Single-Cell Analysis Transcriptomics Market

Single-Cell Analysis Transcriptomics Market Analysis

The Single-Cell Analysis Transcriptomics Market size is estimated at USD 2.00 billion in 2025, and is expected to reach USD 4.16 billion by 2030, at a CAGR of 15.73% during the forecast period (2025-2030).

Key drivers of the single-cell analysis transcriptomics market include advancements in sequencing technologies, heightened research initiatives, and increased funding for both single-cell and cancer research.

Advancements in sequencing technologies play a pivotal role in propelling the growth of the single-cell analysis transcriptomics market. For instance, in February 2024, Parse Biosciences introduced version 3 kits for its flagship Evercode Whole Transcriptome products. These updates promise researchers a streamlined workflow, greater fixation flexibility, and reagents fine-tuned for heightened gene detection sensitivity. Such enhancements are set to elevate the single-cell transcriptomics market by facilitating more accurate and scalable gene analysis. Similarly, in January 2024, Singleron Biotechnologies unveiled two commercial products: the AccuraSCOPE Single Cell Transcriptome and Genome Library Kit and the AccuraSCOPE Single Cell Full-Length Transcriptome Library Kit. Compatible with automation workstations, flow cytometry cell sorting, and micropipette aspiration, these kits enhance Singleron’s FocuSCOPE product line. They enable simultaneous 3’ RNA transcriptome and targeted gene sequencing analysis, marking a significant leap in efficiency and multi-dimensional analysis capabilities for the single-cell transcriptomics market.

Funding initiatives, especially in single-cell and cancer research, are anticipated to boost the market’s growth further. For instance, in September 2023, the National Institutes of Health secured an initial USD 11 million funding for its Multi-Omics for Health and Disease Consortium. This initiative aims to expedite the generation and analysis of multi-omic data, including transcriptomics, thereby spurring innovation in domains like single-cell transcriptomics and bolstering market growth.

In conclusion, the combination of technological advancements, robust research initiatives, and substantial funding is driving the single-cell transcriptomics market.

However, the prohibitive costs associated with equipment and analysis significantly restrain the market’s expansion.

Single-Cell Analysis Transcriptomics Market Trends

The Drug Discovery Segment is Expected to Witness Significant Growth Over the Forecast Period

Single-cell analysis transcriptomics provides detailed insights into cellular heterogeneity, accelerating the identification and development of novel therapeutic agents.

Market growth is primarily driven by the rising use of single-cell analysis transcriptomics in drug discovery, development, and the clinical trial pipeline. For instance, an April 2023 report in the Nature Reviews Drug Discovery Journal highlighted that single-cell analysis transcriptomics is transforming drug discovery. It enhances target identification, deepens disease understanding through cell subtyping, and refines preclinical model selection. Additionally, scRNA-seq supports clinical development by enabling precise biomarker identification for patient stratification and drug response monitoring. These advancements in drug discovery and development directly drive the growth of the single-cell analysis transcriptomics market.

Technological advancements in drug discovery further propel this segment's growth. A March 2023 report in ACS Medicinal Chemistry Letters noted that recent advancements in gene expression and cell morphology assays significantly impact drug discovery. This shift is driven by the need for early-stage assays with clinical predictivity for efficacy and safety. Innovations such as RNA-Seq, DRUG-Seq, TempO-Seq, and Cell Painting have facilitated large-scale data generation for biological readouts. While these systems-level, hypothesis-free approaches are promising, they require validation in drug discovery to ensure predictive utility and compatibility with traditional technologies, emphasizing the necessity for continuous validation in real-world pharmaceutical contexts.

Similarly, the increasing number of innovative product launches is also expected to propel the segment's growth. For instance, in April 2024, Takara Bio USA, Inc. launched the Shasta Single-Cell System, an advanced automated NGS solution designed to enhance discovery in oncology research. This system improves efficiency and reduces costs by streamlining genomic and transcriptomic data extraction from a significantly higher number of cells. Such innovations are expected to drive advancements in drug discovery within the single-cell analysis transcriptomics market by providing deeper insights into cellular functions.

In conclusion, the growing application of single-cell analysis transcriptomics in drug discovery and technological advancements are accelerating the development of new therapeutic agents and significantly driving market growth.

North America is Expected to Hold a Significant Share in the Market Over the Forecast Period

Advancements in sequencing technologies and the increasing number of research initiatives are significant drivers of market growth in North America, owing to which the region accounts for a significant market share.

For instance, in June 2024, Bio-Rad Laboratories, Inc. introduced the ddSEQ Single-Cell 3’ RNA-Seq Kit alongside its Omnition v1.1 analysis software, advancing single-cell transcriptome and gene expression research. The ddSEQ kit, optimized for use with Bio-Rad’s droplet-based cell isolation system, offers a rapid, efficient, and cost-effective workflow for single-cell gene expression studies. This launch significantly expands the single-cell analysis transcriptomics market by enhancing accessibility and streamlining research capabilities.

Similarly, in April 2024, Takara Bio USA, Inc. introduced the Shasta Single-Cell System, an advanced automated NGS solution featuring robust chemistries and user-friendly bioinformatics tools for oncology research. This system enhances researchers’ ability to extract greater genomic and transcriptomic data from a larger number of cells, optimizing efficiency and reducing costs. The launch of such technologies is expected to drive advancements in North America’s single-cell analysis transcriptomics market by enabling more comprehensive biomarker discovery.

Moreover, the rising funding initiatives are also expected to boost the region’s single cell analysis transcriptomics market. For instance, in December 2023, Parse Biosciences secured USD 50 million in financing through a Series C equity raise led by Soleus Capital, with participation from several investors, and a debt facility provided by Horizon Technology Finance Corporation. This brought the company’s total funding to over USD 100 million, enabling it to expand and scale its single-cell sequencing solutions to meet growing demand. The recent funding positions Parse Biosciences to further drive innovation and growth in the North American market.

In conclusion, the advancements in sequencing technologies, the launch of innovative research tools, and rising funding initiatives are propelling growth in North America’s single-cell analysis transcriptomics market by enhancing research efficiency and expanding capabilities.

Single-Cell Analysis Transcriptomics Industry Overview

The single-cell analysis transcriptomics market is competitive, with key players commanding a significant share of the market. Technological advancements and product innovation will provide new opportunities for companies to compete within the market. Some of the major players include 10x Genomics, Bio-Rad Laboratories, Inc., Cytena GmBH, Illumina PLC, and Qiagen NV.

Single-Cell Analysis Transcriptomics Market Leaders

Single-Cell Analysis Transcriptomics Market News

• March 2024: 10x Genomics, Inc. launched its Visium HD Spatial Gene Expression product, which allows researchers to analyze the entire transcriptome from FFPE tissue sections with single-cell resolution.
• February 2024: NanoString Technologies, Inc. launched the CosMx Human 6K Discovery Panel, the first single-cell spatial panel that allows researchers to measure over 6,000 RNA targets across nearly all human biological pathways. In conjunction with this launch, NanoString and independent researchers presented advancements in whole transcriptome imaging, a significant leap in spatial biology.